A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
about
Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancerBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaAdditional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patientsBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaThe use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation.Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipientsEarly use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trialConverting cancer therapies into cures: lessons from infectious diseasesEmpirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.Pharmacokinetic evaluation of piperacillin-tazobactam.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.Piperacillin-tazobactum plus amikacin versus ceftazidime plus amikacin as empirical therapy for Fever in neutropenic patients with hematological malignancies.Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience.Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.Bacteremia in patients with hematological malignancies.A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q24201136-94D54ACA-B48E-4ED5-BDF4-C28755DACACEQ24201767-3D58FD53-C7A2-42CF-AD6A-7F2EC6E14A04Q24246468-8760A237-36C8-4071-AB73-DCD787C7C18AQ24248048-2D310E65-2C05-4996-BED5-2076AD2BCBF3Q31024483-D5FBBC31-8392-4F7B-9EB5-60AA2D339301Q34114674-0984B6CB-2512-40B6-ACCC-0F86AB759419Q34180913-0266CD92-CABF-4869-AAD1-154F78892D3AQ35033597-CC2CDE46-76AE-4D99-A298-7AF9DE59A823Q35047852-AC83FE2C-814E-4118-8A83-C062E2110BACQ36093598-9485F792-EFEA-4802-962E-FC66BB3A1A4AQ36301709-3EECBE00-5F30-4D27-ABB5-1E869241FE7FQ36496470-177BCB67-37FA-425F-A433-D73B6E48FF16Q36607415-4E9E970D-A6D5-4255-898C-6249B589C617Q36839703-571AE7E2-8AEE-4893-BE74-FE3CE7F1273DQ37773368-4B0ED026-A27D-444F-ACF3-2441FFA60289Q38117578-4C85D141-833A-4774-947A-0AAFFC250304Q38620812-AB123B27-2331-46B3-B16F-5BC796B40C7AQ38747206-ACE5C1D0-803C-4816-AF68-099488D3877DQ39024862-99235354-0E5C-486F-9596-32E242C58F3CQ39220949-B6AE94C5-9C97-48A2-9066-B8D1827B4A3FQ40275670-41EA2EAB-A117-4D72-B548-369C58F11EFFQ40321694-139866AC-75AC-45B7-AF6E-BDE07A7566F7Q40324601-F80382DF-1CE7-4E5E-918A-ED5277685A3EQ40346737-0CE5ECDC-FA01-4FFC-BEC0-D8259826995CQ40419049-99696730-D562-45AB-8B3F-59498B8A7402Q40484723-30566508-4084-413C-A01F-D0BD354BC601Q40496949-DE64BF47-3F45-4ACD-98BC-B8757CA05148Q40503352-110EE35D-3863-467C-8DE1-AA0BABE45929Q40508848-CCCFF92A-F3FD-454D-BCFF-6A38BC2BC6C7Q45305512-F17B2A45-99C3-4353-8721-393FB44CE3BEQ51617424-3D92BE58-F2F9-4401-8FC7-A678E7228B20
P2860
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
A multicenter, double-blind, p ...... erapy for febrile neutropenia.
@en
type
label
A multicenter, double-blind, p ...... erapy for febrile neutropenia.
@en
prefLabel
A multicenter, double-blind, p ...... erapy for febrile neutropenia.
@en
P2093
P2860
P356
P1476
A multicenter, double-blind, p ...... erapy for febrile neutropenia.
@en
P2093
A Del Favero
D D'Antonio
F Mandelli
F Menichetti
G Bucaneve
Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program
P2860
P304
P356
10.1086/322646
P407
P577
2001-09-14T00:00:00Z